©2025 Stanford Medicine
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Not Recruiting
Trial ID: NCT01206309
Purpose
The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.
Official Title
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Stanford Investigator(s)
Andrew R Rezvani
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Sally Arai
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Inclusion Criteria:
* Planned or completed first allogeneic stem cell transplant (any conditioning regimen, graft source, donor type and GVHD prophylaxis regimen)
* Signed, informed consent and, if applicable, child assent
Exclusion Criteria:
* Inability to comply with study procedures
* Anticipated survival less than 6 months due to co-morbid disease
* Autoimmune disorder or inherited immunodeficiency before HCT
* Diagnosis of late acute or chronic GVHD prior to study enrollment
* Hematologic relapse or chemotherapy refractory disease at restaging within 1 month of HCT or at the time of enrollment (e.g., \> 5% blasts for leukemia; poorly responsive lymphoma)
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Physician Referrals
650-723-0822